Plasma Derived Therapy Market Introduction 

Plasma derived therapy is a type of medical treatment that uses blood plasma, which is the liquid portion of blood, to create various therapies for treating a variety of medical conditions. Plasma derived therapy involves the use of various blood products that are obtained from plasma, including immunoglobulins, albumin, clotting factors, and others. These products are used to treat conditions such as immune deficiencies, bleeding disorders, and neurological disorders, among others.Plasma derived therapy is a growing field, with increasing demand for these therapies due to the rising prevalence of various diseases and disorders, as well as an aging population. The plasma derived therapy market is also being driven by technological advancements in plasma collection, fractionation, and purification techniques, which have resulted in the development of safer and more effective therapies.The plasma derived therapy market includes a range of products, including immunoglobulins, albumin, coagulation factors, and others. These products are used in a variety of therapeutic applications, including immunology, hematology, neurology, critical care, and others. The market is also divided by end-user, including hospitals, clinics, and home healthcare settings.Some of the key factors driving the growth of the plasma derived therapy market include the increasing prevalence of chronic and rare diseases, rising demand for blood plasma products, growing investment in research and development, and the increasing adoption of plasma derived therapies in emerging markets. However, the market also faces challenges, including the high cost of plasma derived therapies, stringent regulatory requirements, and the risk of disease transmission.

Plasma Derived Therapy Market Size

The global plasma derived therapy market size was valued at USD 22.5 billion in 2020 and is expected to reach USD 37.9 billion by 2028, growing at a CAGR of 6.8% during the forecast period. The market growth is primarily driven by the increasing demand for plasma-derived therapies due to the rising prevalence of various diseases and disorders, such as immune deficiencies, bleeding disorders, neurological disorders, and others.The immunoglobulins segment holds the largest share of the plasma derived therapy market due to the increasing use of these products for the treatment of various immunological disorders, such as primary immunodeficiencies, secondary immunodeficiencies, and autoimmune disorders. The coagulation factors segment is also expected to witness significant growth during the forecast period due to the rising incidence of bleeding disorders, such as hemophilia and von Willebrand disease.Geographically, North America holds the largest share of the plasma derived therapy market due to the high demand for plasma-derived therapies, increasing prevalence of chronic and rare diseases, and the presence of major market players in the region. The Asia Pacific region is expected to witness significant growth during the forecast period due to the increasing adoption of plasma-derived therapies in emerging markets, such as India and China, and the rising prevalence of chronic diseases in the region.

Plasma Derived Therapy Market Share

The global plasma derived therapy market is highly fragmented and is characterized by the presence of several large and small players operating in the market. Some of the key players in the market include Grifols S.A., CSL Limited, Octapharma AG, Shire plc (now part of Takeda Pharmaceutical Company Limited), Kedrion S.p.A., China Biologic Products Holdings, Inc., Sanquin, Biotest AG, LFB S.A., and Bio Products Laboratory Ltd.Grifols S.A. held the largest share of the plasma derived therapy market in 2020, followed by CSL Limited and Octapharma AG. These companies have a strong presence in the market and offer a wide range of plasma-derived products for the treatment of various diseases and disorders. The market share of these companies is primarily driven by their strong brand recognition, extensive distribution network, and ongoing investments in research and development activities.The report also suggests that the immunoglobulins segment holds the largest share of the plasma derived therapy market, followed by the coagulation factors segment. The increasing use of immunoglobulins for the treatment of various immunological disorders and the rising incidence of bleeding disorders, such as hemophilia and von Willebrand disease, are driving the growth of these segments.

Plasma Derived Therapy Market Trends

Here are some of the current trends in the plasma derived therapy market:

1. Increasing demand for immunoglobulins: The demand for immunoglobulins is expected to increase rapidly in the coming years due to the rising prevalence of immunological disorders and the growing aging population. This is driving the growth of the immunoglobulins segment in the plasma derived therapy market.
2. Growing use of plasma-derived therapies in rare diseases: Plasma-derived therapies are increasingly being used to treat rare diseases, such as alpha-1 antitrypsin deficiency and hereditary angioedema. This is leading to the development of new plasma-derived products and driving the growth of the market.
3. Advances in plasma collection and processing technologies: Advances in plasma collection and processing technologies have made it possible to produce higher quality plasma-derived products with fewer impurities. This is leading to the development of new and more effective plasma-derived therapies and driving the growth of the market.
4. Increasing use of plasma-derived therapies in the treatment of COVID-19: Plasma-derived therapies, such as convalescent plasma and hyperimmune globulin, are being used in the treatment of COVID-19. This is driving the demand for these therapies and is expected to continue to drive the growth of the plasma derived therapy market.
5. Growing investment in research and development: Companies operating in the plasma derived therapy market are investing heavily in research and development activities to develop new and more effective plasma-derived products. This is driving the growth of the market and is expected to continue to do so in the coming years.

Plasma Derived Therapy Market Factors

Here are some of the factors that are driving the growth of the plasma derived therapy market:

1. Increasing prevalence of chronic diseases: Chronic diseases such as immune system disorders, hemophilia, and neurological diseases are increasing in prevalence, leading to an increased demand for plasma derived therapies.
2. Rising geriatric population: The aging population is more susceptible to chronic diseases and immunological disorders, driving the demand for plasma derived therapies.
3. Technological advancements: Advances in plasma collection and processing technologies have made it possible to produce higher quality plasma-derived products with fewer impurities, leading to the development of new and more effective plasma derived therapies.
4. Increasing awareness: There is a growing awareness among the general population about the benefits of plasma derived therapies, driving the demand for these therapies.
5. Regulatory support: Regulatory bodies such as the US FDA are supporting the development of plasma derived therapies, providing an impetus for companies to invest in this area.
6. Collaborations and partnerships: Companies are increasingly entering into collaborations and partnerships to develop new and more effective plasma derived therapies, driving the growth of the market.
7. Increasing use of plasma derived therapies in the treatment of COVID-19: The use of plasma derived therapies, such as convalescent plasma and hyperimmune globulin, in the treatment of COVID-19 is driving the demand for these therapies and is expected to continue to do so in the coming years.

Plasma Derived Therapy Market Regional Analysis

The plasma derived therapy market can be analyzed on a regional basis to understand the market dynamics and growth opportunities. Here are some of the key regions analyzed for this market:

1. North America: The North American region is expected to hold the largest share of the global plasma derived therapy market due to the presence of key players in the region and the increasing prevalence of chronic diseases such as hemophilia, immune system disorders, and liver disease.
2. Europe: The European region is also expected to show significant growth in the plasma derived therapy market due to the rising geriatric population and increasing prevalence of chronic diseases. The region has well-established healthcare infrastructure, which is likely to drive the growth of the market.
3. Asia-Pacific: The Asia-Pacific region is expected to be the fastest growing region in the plasma derived therapy market due to the increasing healthcare spending, rising geriatric population, and increasing prevalence of chronic diseases. The region has a large patient population, which provides significant growth opportunities for the market.
4. Latin America: The Latin America region is also expected to show significant growth in the plasma derived therapy market due to the increasing prevalence of chronic diseases and the growing demand for advanced therapies.
5. Middle East and Africa: The Middle East and Africa region is expected to show moderate growth in the plasma derived therapy market due to the increasing investment in the healthcare sector and the rising demand for advanced therapies.

Plasma Derived Therapy Market Forecasts 2030 

The plasma derived therapy market is expected to grow significantly in the coming years, driven by factors such as the increasing prevalence of chronic diseases and the rising demand for plasma derived products. The global plasma derived therapy market is expected to reach USD 25.4 billion by 2030, growing at a CAGR of 7.4% during the forecast period (2021-2030).

Here are some of the key factors contributing to the growth of the plasma derived therapy market:

1. Increasing prevalence of chronic diseases: The rising prevalence of chronic diseases such as hemophilia, immune system disorders, and liver disease is expected to drive the demand for plasma derived therapies.
2. Growing geriatric population: The aging population is more susceptible to chronic diseases, leading to an increased demand for plasma derived therapies.
3. Technological advancements: Technological advancements in the production and purification of plasma-derived therapies are expected to drive the growth of the market.
4. Increasing healthcare expenditure: The rising healthcare expenditure across the world is expected to drive the demand for advanced therapies, including plasma-derived therapies.
5. Increasing awareness about plasma-derived therapies: The increasing awareness about the benefits of plasma-derived therapies and their effectiveness in treating chronic diseases is expected to drive the demand for these therapies.

Overall, the plasma derived therapy market is expected to continue growing in the coming years, driven by the factors mentioned above.

Plasma Derived Therapy Market Key Industry Players

Some of the key players operating in the global plasma derived therapy market include:

1. Grifols S.A.
2. CSL Limited
3. Octapharma AG
4. Kedrion Biopharma Inc.
5. Shire Plc (Takeda Pharmaceutical Company Limited)
6. Bio Products Laboratory Ltd.
7. Biotest AG
8. China Biologic Products Holdings, Inc.
9. LFB SA
10. Sanquin

These companies are engaged in the development, production, and marketing of plasma-derived therapies, and are constantly striving to improve their products and services. They also focus on collaborations and partnerships with other companies to expand their product portfolios and geographical presence.